» Articles » PMID: 36154322

Chronic Pulmonary Aspergillosis Infection in Coal Workers Pneumoconiosis With Progressive Massive Fibrosis

Overview
Authors
Affiliations
Soon will be listed here.
Abstract

Pneumoconiosis is associated with coal dust particles depositing within the lung causing nodules coalesce to form progressive massive fibrosis (PMF). Cavitary lesions can develop in these PMF areas for concerns of tuberculosis and aspergillosis. We present a 59-year-old patient who had coal workers pneumoconiosis and PMF presenting with chronic dyspnea and hemoptysis with an upper cavitary lesion noted on chest imaging. He notes dyspnea with walking very short distances with associated productive cough. He admits to occasional wheezing, paroxysmal dyspnea, hemoptysis, and orthopnea but denies chest pain. He is an everyday smoker. His physical examination was only remarkable for bronchial breath sounds. On review of his prior imaging, he had a right upper lobe infiltrate as far back as 2012. As the years progressed, a new cavitary lesion developed in the PMF area which progressively got larger with a thick wall and no eccentric region noted inside the cavity. Tuberculosis test was negative. He underwent a transbronchial biopsy with methenamine silver stain which showed acute angle branching and septation suggestive of species. He was diagnosed with pulmonary aspergillosis and treated with voriconazole for 1 year. With pneumoconiosis and evidence confirming aspergillosis, the presence of a new lung infiltration with progression into a cavitary lesion leads to a diagnosis of chronic cavitary pulmonary aspergillosis (CCPA). With follow-up imaging showing extensive lung fibrosis, he had chronic fibrosing pulmonary aspergillosis (CFPA), a late-stage manifestation of CCPA.

Citing Articles

Application of mNGS in the study of pulmonary microbiome in pneumoconiosis complicated with pulmonary infection patients and exploration of potential biomarkers.

Yuan X, Xie L, Shi Z, Zhou M Front Cell Infect Microbiol. 2023; 13:1200157.

PMID: 37545858 PMC: 10403237. DOI: 10.3389/fcimb.2023.1200157.

References
1.
Bhopalwala H, Mishra V, Do T, Gudipati M, Ganti S . COVID-19 Infection and Late Manifestation of Pulmonary Aspergillosis. J Investig Med High Impact Case Rep. 2022; 10:23247096211063332. PMC: 8744194. DOI: 10.1177/23247096211063332. View

2.
Kato T, Usami I, Morita H, Goto M, Hosoda M, Nakamura A . Chronic necrotizing pulmonary aspergillosis in pneumoconiosis: clinical and radiologic findings in 10 patients. Chest. 2002; 121(1):118-27. DOI: 10.1378/chest.121.1.118. View

3.
Ouchi H, Fujita M, Ikegame S, Inoshima I, Harada E, Nakanishi Y . Successful treatment of refractory chronic necrotizing pulmonary aspergillosis with micafungin. J Infect Chemother. 2007; 13(4):258-62. DOI: 10.1007/s10156-007-0524-9. View

4.
Camuset J, Nunes H, Dombret M, Bergeron A, Henno P, Philippe B . Treatment of chronic pulmonary aspergillosis by voriconazole in nonimmunocompromised patients. Chest. 2007; 131(5):1435-41. DOI: 10.1378/chest.06-2441. View

5.
Patterson T, Thompson 3rd G, Denning D, Fishman J, Hadley S, Herbrecht R . Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America. Clin Infect Dis. 2016; 63(4):e1-e60. PMC: 4967602. DOI: 10.1093/cid/ciw326. View